Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples.
about
Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu statusExpression of KIT receptor tyrosine kinase in endothelial cells of juvenile brain tumorsLong-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testingChromogenic in situ hybridization compared with other approaches to evaluate HER2/neu status in breast carcinomasHER2 testing: a review of detection methodologies and their clinical performanceGold-facilitated in situ hybridization: a bright-field autometallographic alternative to fluorescence in situ hybridization for detection of Her-2/neu gene amplification.Amplification of c-myc oncogene by chromogenic and fluorescence in situ hybridization in archival breast cancer tissue array samples.Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.RCL2, a new fixative, preserves morphology and nucleic acid integrity in paraffin-embedded breast carcinoma and microdissected breast tumor cells.Proto-oncogene HER-2 in normal, dysplastic and tumorous feline mammary glands: an immunohistochemical and chromogenic in situ hybridization studyEpidermal growth factor receptor (EGFR) gene copy number detection in non-small-cell lung cancer; a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization.HER-2/neu amplification testing in breast cancer by Multiplex Ligation-dependent Probe Amplification: influence of manual- and laser microdissection.Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistryQuantitative real-time RT-PCR and chromogenic in situ hybridization: precise methods to detect HER-2 status in breast carcinomaImmunostaining with D2-40 improves evaluation of lymphovascular invasion, but may not predict sentinel lymph node status in early breast cancerEpidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis.The prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer.Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification.HER-2/neu oncogene amplification by chromogenic in situ hybridization in 130 breast cancers using tissue microarray and clinical follow-up studies.Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimensEpidermal growth factor receptor gene amplification in atypical adenomatous hyperplasia of the lung.Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinomaChromogenic in situ hybridization analysis of HER-2/neu status in breast carcinoma: application in screening of patients for trastuzumab (Herceptin) therapy.Dual color chromogenic in situ hybridization for determination of HER2 status in breast cancer: a large comparative study to current state of the art fluorescence in situ hybridization.Polysialic acid is associated with better prognosis and IDH1-mutation in diffusely infiltrating astrocytomas.Chromogenic in situ hybridization to detect EGFR gene copy number in cell blocks from fine-needle aspirates of non small cell lung carcinomas and lung metastases from colo-rectal cancerDetermination of HER-2 status on FNAC material from breast carcinomas using in situ hybridization with dual chromogen visualization with silver enhancement (dual SISH).Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray.Chromogenic in situ hybridisation (CISH) is a powerful method to detect ALK-positive non-small cell lung carcinomas.Testing for HER2 in Breast Cancer: A Continuing Evolution.Comparison between immunohistochemistry and chromogenic in situ hybridization in assessing HER-2 status in breast cancer.Prevalence of HER-2 and Hormone Receptors and P53 Mutations in the Pathologic Specimens of Breast Cancer Patients.Combined fluorescent-chromogenic in situ hybridization for identification and laser microdissection of interphase chromosomes.Prognostic and predictive value of HER2/neu oncogene in breast cancer.Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay.Evaluation of intratumoral HER-2 heterogeneity by fluorescence in situ hybridization in invasive breast cancer: a single institution studyGene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung.Comparison of liquid based cytology and histology for the evaluation of HER-2 status using immunostaining and CISH in breast carcinoma.Targeted therapy in breast cancer: the HER-2/neu gene and protein.HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.
P2860
Q21195160-2574FCA7-CD9C-4D95-A161-5823561AD39BQ24614629-22F875B3-CBE6-492A-9B68-B2950051FC33Q24797752-A8B06823-15B8-482D-9F03-11169B2594DEQ26865068-966E55DE-FF60-4D31-8F68-4B82ABBDEDACQ28280488-55EAC208-AE17-48B7-BDA6-2142A028796BQ30444859-7DAD4F4A-6D55-4DE9-9DC1-5B1350C5FA0FQ31029884-DE9BF7ED-B651-4126-8F3E-C65BAFAD1569Q31078568-8E68B4D6-8C4E-4BA0-AEAA-6622CF478A59Q33241448-177DD62D-9E92-4278-99A2-556E8B4D2275Q33299623-8FC4CDA1-3041-4D67-8097-D70C3B0786E2Q33302191-550AE888-2606-4F7F-B8EF-1630B9C9DE1BQ33397620-B99CD4F7-631E-4010-AAB6-87C9CCB61149Q33398141-590AC025-3BB0-4A94-BE68-C753594FBD33Q33421127-39990D93-E9AB-48E4-9548-7CC4FFFE1EE6Q33428339-388E5F51-0125-470B-8593-FB9890296BABQ33497634-810DED15-6DC0-46E5-9801-3E3A123FB565Q33538053-89C37F1C-135A-4AF7-A4AC-E1214E288A42Q33627215-3B91236F-B136-4CA5-92FE-514A0FD9229AQ33631562-C22D43B7-9158-472D-BDB3-039EB49E8A8BQ33794421-7D4E933F-683C-427B-AA29-4552BFB60EAEQ33942092-BA26869B-E81A-43AD-8FDB-8F4BF1D7C5EBQ34064466-EC81C0F3-7CD1-40AD-9C04-975760219298Q34091814-5C61E595-533C-44B8-BC00-3A285275AA3FQ34158575-9719E251-F4C0-43D9-8C60-43645741E9ACQ34169068-77D02C3F-D21B-4AEA-A04D-06C386FBB6F1Q34198721-C3B089A6-2F68-4901-ABEF-6C9AC9E09E38Q34204064-6C7961F3-8264-4215-B13B-4ED0E71F6763Q34247041-1EECF160-AF07-4BBE-BF81-36D55CE970A9Q34389047-6F22A2C4-35C6-4A94-8790-F20D39F1A2F1Q34424285-235ED034-7364-4580-9F3F-C12982A48C16Q34424833-34F2D85B-8397-491E-B6F2-55E09F9A9A74Q34575276-4E8E8260-365E-4712-B556-3D59B4CE59DCQ34658220-5CF57169-62EA-41C7-928D-6AA521B8C0AFQ34954864-72F69C78-3CE4-42D6-86CB-7184CF8BA23CQ35017477-EBD00668-4190-4D70-8566-D28DC17FF4D6Q35158754-ACCD5F06-3BA6-4D01-9A03-D5C3845419F5Q35588760-8EF63E57-6886-433D-B1EA-E2F481CA6A2DQ35589112-8A3E1C42-2A99-4619-8E2D-84096B44885FQ35648508-F68B36DA-F11F-4FB5-8DC7-75B3B6BAF08BQ35744973-F49C4DF4-3E33-4F09-BDB0-128DC4685A83
P2860
Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples.
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Chromogenic in situ hybridizat ...... rchival breast cancer samples.
@ast
Chromogenic in situ hybridizat ...... rchival breast cancer samples.
@en
type
label
Chromogenic in situ hybridizat ...... rchival breast cancer samples.
@ast
Chromogenic in situ hybridizat ...... rchival breast cancer samples.
@en
prefLabel
Chromogenic in situ hybridizat ...... rchival breast cancer samples.
@ast
Chromogenic in situ hybridizat ...... rchival breast cancer samples.
@en
P2093
P2860
P1476
Chromogenic in situ hybridizat ...... rchival breast cancer samples.
@en
P2093
D Gancberg
D Larsimont
M J Piccart
P2860
P304
P356
10.1016/S0002-9440(10)64785-2
P407
P577
2000-11-01T00:00:00Z